Novo Nordisk diversifies with $2.1bn deal to buy CorvidiaNovo Nordisk has taken another step towards expanding beyond its heartlands of diabetes and obesity with a deal Share XNovo Nordisk diversifies with $2.1bn deal to buy Corvidiahttps://pharmaphorum.com/news/novo-nordisk-diversifies-with-2-1bn-deal-to-buy-corvidia/
3 key trends shaping the immunology marketFrom an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an Share X3 key trends shaping the immunology markethttps://pharmaphorum.com/views-analysis-market-access/3-key-trends-shaping-the-immunology-market/
